Search results
- Regulatory news (469) Apply Regulatory news filter
- Press releases (175) Apply Press releases filter
- Basic page (37) Apply Basic page filter
- Pipeline (19) Apply Pipeline filter
- Corporate presentations (17) Apply Corporate presentations filter
- Shareholder meeting (17) Apply Shareholder meeting filter
- Team member (16) Apply Team member filter
- Videos (14) Apply Videos filter
- Financial reports (9) Apply Financial reports filter
- Analyst (7) Apply Analyst filter
- Event (7) Apply Event filter
- Investor contact (6) Apply Investor contact filter
- Webcasts and audio (6) Apply Webcasts and audio filter
- Research (3) Apply Research filter
- Financial calendar (1) Apply Financial calendar filter
Vectors with safety features
Oxford BioMedica’s LentiVector® platform is designed to give the highest safety and efficacy.
Automation and robotics
The LentiVector® platform integrates automated systems enabling scalable and cost-effective manufacture of lentiviral vectors.
200L serum-free suspension cell culture
Oxford BioMedica established serum-free suspension production processes to enhance vector output.
Data analytics and artificial intelligence
Oxford BioMedica is introducing Data Analytics and Artificial Intelligence in its systems to improve productivity and product quality
AXO–LENTI–PD (Axovant)
AXO–LENTI–PD
Gene-based treatment for Parkinson's disease
Status: Phase I/IIa study in preparation
SAR 422459 (Sanofi)
SAR422459
Gene therapy for Stargardt disease
Licensed to Sanofi: Phase II ongoing
OXB-202
OXB-202
Gene-based treatment for corneal graft rejection
Status: Phase I/II study in preparation
OXB–302
OXB-302
Gene-based immunotherapy targeting a range of cancers
Status: Pre–Clinical complete
OXB–201
OXB-201
Gene therapy for wet age-related macular degeneration
Status: Phase I trial complete
SAR 421869 (Sanofi)
SAR 421869
Gene therapy for Usher syndrome type 1B
Licensed to Sanofi: Phase I/IIa trial ongoing